{"doi":"10.2337/figshare.16826671.v1","title":"Glucagon Clearance is Preserved in Type 2 Diabetes","abstract":"<jats:p>Hyperglucagonemia is a common observation in both obesity and type 2\ndiabetes, and the etiology is primarily thought to be hypersecretion of\nglucagon. We investigated whether altered elimination kinetics of glucagon\ncould contribute to the hyperglucagonemia in type 2 diabetes and obesity&lt;i&gt;. &lt;/i&gt;Individuals with type 2 diabetes and\npreserved kidney function (8 with and 8 without obesity) and matched control individuals\n(8 with and 8 without obesity) were recruited. Each participant underwent a 1-hour\nglucagon infusion (4 ng/kg/min), achieving steady-state plasma glucagon concentrations,\nfollowed by a 1-hour wash-out period. Plasma levels, the metabolic clearance\nrate (MCR), half-life (T&lt;sub&gt;½&lt;/sub&gt;) and volume of distribution of glucagon were evaluated and a\npharmacokinetic model was constructed.&lt;i&gt; &lt;/i&gt;Glucagon\nMCR and volume of distribution were significantly higher in the type 2 diabetes\ngroup compared to the control group, while no significant differences between\nthe groups were found in glucagon T&lt;sub&gt;½&lt;/sub&gt;. Individuals with obesity had neither a significantly\ndecreased MCR, T&lt;sub&gt;½&lt;/sub&gt;, nor volume of distribution of glucagon. In our pharmacokinetic model,\nglucagon MCR associated positively with fasting plasma glucose and negatively\nwith body weight. In conclusion, our results suggest that impaired glucagon\nclearance is not a fundamental part of the hyperglucagonemia observed in obesity\nand type 2 diabetes.</jats:p>","journal":"Figshare","year":null,"id":41480,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":197419,"name":"Asger Lund","orcid":null,"position":1,"is_corresponding":false},{"id":197420,"name":"Jonatan I. Bagger","orcid":null,"position":2,"is_corresponding":false},{"id":197421,"name":"Tonny S. Petersen","orcid":null,"position":3,"is_corresponding":false},{"id":197422,"name":"Nicolai J. Wewer Albrechtsen","orcid":null,"position":4,"is_corresponding":false},{"id":197423,"name":"Jens J. Holst","orcid":null,"position":5,"is_corresponding":false},{"id":197424,"name":"Tina Vilsbøll","orcid":null,"position":6,"is_corresponding":false},{"id":197425,"name":"Mikkel B. Christensen","orcid":null,"position":7,"is_corresponding":false},{"id":197426,"name":"Filip K. Knop","orcid":"0000-0002-2495-5034","position":8,"is_corresponding":false},{"id":197417,"name":"Magnus F.G. Grøndahl","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18998881","pmcid":null,"openalex_id":"https://openalex.org/W4207081811","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.27483006,"influential_citations":0,"citation_trend":[],"oa_status":"green","license":"cc-by-nc-sa","oa_locations":[{"url":"https://figshare.com/articles/figure/Glucagon_Clearance_is_Preserved_in_Type_2_Diabetes/16826671","host_type":"repository"},{"url":"https://figshare.com/articles/figure/Glucagon_Clearance_is_Preserved_in_Type_2_Diabetes/16826671","host_type":"repository"},{"url":"https://doi.org/10.2337/figshare.16826671.v1","host_type":""}],"fields_of_study":["Diabetes Treatment and Management","Diabetes Management and Research","Hyperglycemia and glycemic control in critically ill and hospitalized patients"],"mesh_terms":[],"keywords":["Hyperglucagonemia","Glucagon","Endocrinology","Internal medicine","Type 2 diabetes","Volume of distribution","Diabetes mellitus","Medicine","Type 1 diabetes","Obesity","Pharmacokinetics","Chemistry","Insulin"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-13T01:22:01.965172Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}